TAS1R1, TAS1R3, TLR2, TLR4, CA6 Gene Polymorphism on Dental Caries

Sponsor
Recep Tayyip Erdogan University Training and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04066101
Collaborator
(none)
200
1
22.1
9

Study Details

Study Description

Brief Summary

The aim of this study is to examine the effects of TAS1R1, TAS1R3, TLR2, TLR4, CA6, gene polymorphism on caries risk in adults.

Condition or Disease Intervention/Treatment Phase
  • Genetic: high caries risk
  • Other: caries activity

Detailed Description

To date, genes can be grouped into categories based on the factor influencing dental caries. The major candidate gene categories to date include enamel formation genes, immune response genes, genes related to saliva, and genes related to taste and dietary habits.

CA6 exists in the human saliva and has a critical role of buffering, immune response and taste.Toll-like receptors are expressed in the tongue gustatory papillae where they may initiate immune responses to pathogens.Genetic variations in the TAS1R1 and TAS1R3 for umami cause perception of these tastes differently.

Study Design

Study Type:
Observational
Actual Enrollment :
200 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Variants in Taste Genes on Caries Risk and Caries Activity Status
Actual Study Start Date :
Jan 15, 2018
Actual Primary Completion Date :
Oct 15, 2019
Actual Study Completion Date :
Nov 20, 2019

Arms and Interventions

Arm Intervention/Treatment
high caries risk

100 adults will be allowed in the high caries risk group according to DMFT index (DMFT ≥ 14)

Genetic: high caries risk
DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
Other Names:
  • DNA isolation, genotyping
  • Other: caries activity
    Dental caries lesions of all patient scored as initial, moderate or advanced caries Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed

    low caries risk

    100 adults will be allowed in the low caries risk group according to DMFT index (DMFT ≤ 5)

    Genetic: high caries risk
    DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
    Other Names:
  • DNA isolation, genotyping
  • Other: caries activity
    Dental caries lesions of all patient scored as initial, moderate or advanced caries Initial lesion; clinically detectable lesion Moderate; visible signs of enamel breakdown Advanced; enamel was fully cavitaed

    Outcome Measures

    Primary Outcome Measures

    1. Past caries experience [4 months]

      Each tooth will be examined and recorded as decayed, missing, or filled (DMFT). Caries will be defined in accordance with the World Health Organization (WHO 1997) criteria.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Years to 44 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • adult be between 25 and 44 years old

    • subject has DMFT (Decayed, Missing, Filled, Permanent Tooth) ≥ 5, or, DMFT ≥14

    • same oral health, diet and socioeconomic status

    Exclusion Criteria:
    • systemic or genetic disorders

    • orthodontic appliances

    • pregnant women

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Recep Tayyip Erdogan University Rize Turkey 53000

    Sponsors and Collaborators

    • Recep Tayyip Erdogan University Training and Research Hospital

    Investigators

    • Principal Investigator: Gül Yıldız Telatar, Dr., Recep Tayyip Erdogan University Dentistry Faculty

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Gul Yildiz Telatar, Principal Investigator, Recep Tayyip Erdogan University Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT04066101
    Other Study ID Numbers:
    • 2016/30
    First Posted:
    Aug 26, 2019
    Last Update Posted:
    Apr 15, 2021
    Last Verified:
    Apr 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Gul Yildiz Telatar, Principal Investigator, Recep Tayyip Erdogan University Training and Research Hospital

    Study Results

    No Results Posted as of Apr 15, 2021